Covid 19 Clinical Trial
Official title:
A Single-Blind, Randomized, Placebo Controlled, Study to Evaluate the Benefits and Safety of Endourage Targeted Wellness Formula C™ Sublingual Drops in People With Post -Acute COVID-19 Syndrome (PACS).
This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".
At present, conventional medical and rehabilitation therapies have not consistently been effective for people with PACS, and in fact some symptoms have been observed to worsen over time. This inconsistency in clinical response has created a need for alternative treatment options to be explored. CBD presents a novel approach that warrants further investigation. After review and approval by an Institutional Review Board (IRB), potential study participants will be recruited from on-line support groups who have identified themselves as persons experiencing post-acute COVID-19 syndrome also known as (long-haulers syndrome). The study will be registered on the www.clincaltrials.gov website and will accept referrals from targeted clinics who refer their patients to the investigational site listed and individuals can also self-refer to the study center team. Subjects will be evaluated weekly using telemedicine procedures. At completion of study, there will be a 7-day and 14-day follow up telemedicine visit to assess for continued benefit and/or re-emergence of symptoms/relapse. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04333732 -
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
|
Phase 3 | |
Completed |
NCT04357457 -
Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia
|
Phase 3 | |
Terminated |
NCT04435795 -
Inhaled Ciclesonide for Outpatients With COVID19
|
Phase 2/Phase 3 | |
Completed |
NCT04357444 -
Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19
|
Phase 2 | |
Completed |
NCT04357834 -
WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
|
||
Not yet recruiting |
NCT05052320 -
Audiological Assessment of Recovered Covid 19 Subjects.
|
||
Withdrawn |
NCT04426344 -
Core Warming of COVID-19 Patients
|
N/A | |
Recruiting |
NCT05595031 -
Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
|
||
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 | |
Terminated |
NCT04401410 -
Anti-SARS Cov-2 T Cell Infusions for COVID 19
|
Phase 1 | |
Completed |
NCT04445337 -
Stellate Ganglion Blockade in COVID-19 Positive Patients
|
N/A | |
Active, not recruiting |
NCT04374487 -
Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications
|
Phase 2 | |
Completed |
NCT04403243 -
COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04375644 -
Impact of the COVID-19 Pandemic on the Quality of Psychological Life (COVID-PRO-IMPACT)
|
||
Completed |
NCT04394078 -
Impact of COVID-19 Pandemic on Depression and Quality of Life
|
||
Recruiting |
NCT04407923 -
Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment
|
||
Completed |
NCT04426305 -
Community Health Workers Against COVID19
|
N/A | |
Withdrawn |
NCT04519411 -
Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure
|
N/A | |
Recruiting |
NCT04492514 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation
|
Phase 2 | |
Completed |
NCT04399980 -
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
|
Phase 2 |